Deciphera Pharmaceuticals Sustainability Profile
Deciphera Pharmaceuticals, a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2003, the company has made significant strides in the oncology sector, particularly with its proprietary drug discovery platform that targets specific molecular pathways. With a strong presence in the US and expanding operations globally, Deciphera is renowned for its core product, ripretinib, which offers a unique approach to treating gastrointestinal stromal tumours (GIST). The company’s commitment to advancing precision medicine has positioned it as a notable player in the industry, achieving key milestones such as successful clinical trials and regulatory approvals. Deciphera Pharmaceuticals continues to drive innovation, aiming to improve patient outcomes through its cutting-edge therapies.
DitchCarbon Score
How does Deciphera Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Deciphera Pharmaceuticals's score of 76 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Deciphera Pharmaceuticals, headquartered in the US, currently does not have specific carbon emissions data available for reporting. As a current subsidiary of Ono Pharmaceutical Co., Ltd., any climate commitments or emissions data may be influenced by the parent company's initiatives. Deciphera Pharmaceuticals has not publicly disclosed any reduction targets or specific climate pledges. However, it is important to note that emissions data and climate strategies may be cascaded from Ono Pharmaceutical Co., Ltd., which is actively engaged in sustainability efforts. As the company continues to develop its environmental strategies, stakeholders can look forward to potential future commitments aligned with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 22,100,000 | - | 0,000,000 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000,000 | - | - | - | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | 00,000,000 | - | - | - | 00,000,000 | - | 000,000,000 | 00,000,000 |
How Carbon Intensive is Deciphera Pharmaceuticals's Industry?
How Carbon Intensive is Deciphera Pharmaceuticals's Location?
Deciphera Pharmaceuticals's Scope 3 Categories Breakdown
Deciphera Pharmaceuticals's Scope 3 emissions, which decreased by 89% last year and decreased by approximately 85% since 2017, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 50% of total emissions under the GHG Protocol, with "Business Travel" being the largest emissions source at 43% of Scope 3 emissions.
Top Scope 3 Categories
Deciphera Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Deciphera Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
